Receptos to Deliver Scientific Presentations at Digestive Disease Week 2013 About the Therapeutic Role of RPC1063 in Inflammato
15 Maggio 2013 - 10:05PM
Receptos (Nasdaq:RCPT) today announced that Company personnel will
deliver three scientific poster presentations about RPC1063 at the
Digestive Disease Week (DDW) annual meeting from May 18 to 21, 2013
at the Orange County Convention Center in Orlando, Florida. DDW
attracts thousands of physicians, researchers and academics from
around the world to share the latest research in gastrointestinal
health topics, for which DDW is the premier scientific conference.
RPC1063 is the Company's lead sphingosine 1- phosphate 1 receptor
(S1P1R) selective modulator in Phase 2 development for both
ulcerative colitis (UC) and relapsing multiple sclerosis (RMS).
Receptos will present two abstracts on Saturday, May 18, 2013.
The first Receptos abstract, titled, "Results of a safety and
tolerability study of RPC1063, a novel orally administered
sphingosine-1-phosphate receptor 1 (S1P1R) agonist, in healthy
adult volunteers," discusses the emerging favorable safety,
pharmacokinetic (PK) and pharmacodynamic (PD) profile for RPC1063
in support of the ongoing Phase 2 clinical development program in
UC.
The second Receptos abstract, titled, "RPC1063, a potent,
selective S1P1 receptor modulator, is active in therapeutic
inflammatory bowel disease models and exhibits favorable PK/PD
properties in healthy volunteers," elucidates the potential profile
of RPC1063 as a potent and selective S1P1R modulator, with
attractive clinical PK features including short half-life to
facilitate rapid lymphocyte recovery.
Receptos will present a third abstract on Tuesday, May 21,
titled, "RPC1063 is a potent S1P1R modulator with efficacy in the
SAMP1/YitFc ileitis model: new evidence for dysregulation of S1P
metabolism in preclinical models and patients with inflammatory
bowel disease." This abstract discusses a possible contributory
role of sphingosine 1- phosphate (S1P) at sites of inflammation
within the intestine of UC patients. This finding is reproducible
in animal models of IBD and may further support the mechanism by
which an S1P1R modulator would play a therapeutic role in the
treatment of IBD. These data were generated in collaboration with
the laboratory of Jesus Rivera-Nieves, MD, from the University of
California, San Diego.
RPC1063 is a novel, differentiated S1P1R selective modulator
exhibiting picomolar potency that is effective in rodent models of
both MS and IBD, and possesses an attractive safety profile in
non-clinical toxicology studies. Receptos completed a Phase 1 study
with RPC1063 which tested single ascending doses, multiple
ascending doses and dose titration regimens in healthy volunteers.
The Phase 1 results confirmed desirable PK, PD and safety features,
which provide support for the differentiation strategy for RPC1063
as a potential best-in-class second-generation S1P1R modulator.
Receptos is currently testing RPC1063 in a Phase 2 study for UC and
a Phase 2/3 study for RMS.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is an S1P1R small molecule
modulator candidate for immune indications, including RMS and IBD.
The Company is also developing RPC4046, an anti-interleukin-13
(IL-13) antibody for an allergic/immune-mediated orphan disease,
eosinophilic esophagitis (EoE). Receptos has established expertise
in high resolution protein crystal structure determination, biology
and drug discovery for G-protein-coupled receptors (GPCRs).
Forward-Looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "expects," "believes," "anticipates," "estimates," "may,"
"could," "intends," "emerging, "elucidates," "potential,"
"possible" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements do not
constitute guarantees of future performance. Investors are
cautioned that forward-looking statements that are not strictly
historical statements, including, without limitation, statements
regarding the development of Receptos' lead product candidate,
RPC1063, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated. These forward-looking statements are based
upon Receptos' current expectations and involve assumptions that
may never materialize or may prove to be incorrect. Actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks associated with the process of discovering, developing and
commercializing drug candidates that are safe and effective for use
as human therapeutics. These and other risks are described in
additional detail in Receptos' SEC filings. All forward-looking
statements contained in this release speak only as of the date on
which they were made. Receptos undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Set 2023 a Set 2024